NICE recommends more people have access to COVID-19 antiviral More people should be eligible to receive the COVID-19 antiviral nirmatrelvir plus ritonavir (Paxlovid), according to new draft guidance from NICE. by Emma Bower Sign in to continue Sign In Email address Password Stay signed in Trouble signing in? Reset password: Click here Need help? Email us Register FREE Limited free articles a month Free email bulletins Register Now Register Now Take a 30-day trial Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days Sign Up Sign Up
